Loading stock data…
Gilead Sciences, Inc. (GILD)
$146.64-4.36 (-2.88%)
Market ClosedLast close Sep 8
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Gilead Sciences, Inc. in the Healthcare sector is trading at $146.64 with a market capitalization of $164.8B. Wall Street consensus targets $157.41 (27 analysts), implying a +7.3% move over the next 12 months. The stock is currently 7% below its 52-week high of $157.29, remaining 9.9% above its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +7.3% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $7.80B↑ | $6.96B↓ | $7.92B↑ | $7.77B↑ | $7.08B |
| Gross Profit | $6.22B↑ | $5.51B↓ | $6.30B↑ | $6.20B↑ | $5.58B |
| Operating Income | $2.54B↓ | $2.69B↓ | $2.99B↓ | $3.50B↑ | $2.72B |
| Net Income | -$10.50B↓ | $2.02B↓ | $2.18B↓ | $3.05B↑ | $1.96B |
Peer Comparison
JNJUNHPFE
Fundamentals
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunl...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$164.77B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.34
Div Yield
Strong income play. Yield provides a meaningful total return floor.
2.20%
ROE
Elite ROE. Management converts capital into profit efficiently.
30.86%
Volume
Today's trading volume
6.02M
Recent News
Bixlenvo Gives Gilead a New HIV Growth Path. How Large is the Market?
Gilead Sciences, Inc. (NASDAQ:GILD) has added another treatment to its HIV portfolio with the FDA approval of Bixlenvo, a once-daily pill for adults whose infection is already suppressed to very low levels. The combination brings together bictegravir, a key component of Gilead’s (NASDAQ:GILD) blockbuster Biktarvy, and lenacapavir, the foundation of the company’s longer-term HIV strategy. […]
IBB Just Beat the S&P 500 by 22 Points in Three Months. Are You Late to the Party?
Biotech just staged one of its sharpest reversals in years, and whether you caught it or completely missed it, the same uncomfortable question now sits in front of every portfolio: does the trade still have teeth, or did the easy money already leave?
Gilead Sciences Just Won Its Third FDA Approval in Less Than 4 Months. Is the Stock Still Underrating This Turnaround Play?
Gilead Sciences is branching out beyond its HIV franchise into oncology and immunology therapies.
Will New HIV and Oncology Approvals Redefine Gilead Sciences' (GILD) Treatment Platform Narrative?
Gilead Sciences recently secured U.S. FDA approval for Bixlenvo, a once-daily single tablet regimen for virologically suppressed adults with HIV on complex regimens, and European Commission approval for Trodelvy plus Keytruda as a first-line treatment for certain PD-L1–positive metastatic triple-negative breast cancer patients. These back-to-back approvals broaden Gilead’s reach in HIV and oncology by addressing hard-to-treat, heavily pretreated populations with simplified or first-in-class...
Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue?
Kymera Therapeutics (KYMR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.